An extended substrate spectrum of the proton organic cation antiporter and relation to other cation transporters.
blood–brain barrier
clinically relevant drugs
hCMEC/D3 cells
organic cation transporter
proton organic cation antiporter
Journal
Basic & clinical pharmacology & toxicology
ISSN: 1742-7843
Titre abrégé: Basic Clin Pharmacol Toxicol
Pays: England
ID NLM: 101208422
Informations de publication
Date de publication:
21 Oct 2024
21 Oct 2024
Historique:
revised:
13
09
2024
received:
10
05
2024
accepted:
16
09
2024
medline:
21
10
2024
pubmed:
21
10
2024
entrez:
21
10
2024
Statut:
aheadofprint
Résumé
Most central nervous system (CNS) active drugs are organic cations, which need carrier proteins for efficient transfer through the blood-brain barrier (BBB). A genetically still unidentified proton organic cation (H
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : 461080000
Organisme : University Medical Center, University of Göttingen
Informations de copyright
© 2024 The Author(s). Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).
Références
Goldberg MJ, Spector R, Chiang CK. Transport of diphenhydramine in the central nervous system. J Pharmacol Exp Ther. 1987;240(3):717‐722.
Sachkova A, Jensen O, Dücker C, Ansari S, Brockmöller J. The mystery of the human proton‐organic cation antiporter: one transport protein or many? Pharmacol Ther. 2022;239:108283. doi:10.1016/j.pharmthera.2022.108283
Kitamura A, Higuchi K, Kurosawa T, Okura T, Kubo Y, Deguchi Y. Naltrexone transport by a proton‐coupled organic cation antiporter in hCMEC/D3 cells, an in vitro human blood‐brain barrier model. Biol Pharm Bull. 2022;45(10):1585‐1589. doi:10.1248/bpb.b22‐00347
Chapy H, André P, Declèves X, Scherrmann JM, Cisternino S. A polyspecific drug/proton antiporter mediates diphenhydramine and clonidine transport at the mouse blood‐retinal barrier. Br J Pharmacol. 2015;172(19):4714‐4725. doi:10.1111/bph.13246
Wang X, Qi B, Su H, et al. Pyrilamine‐sensitive proton‐coupled organic cation (H(+)/OC) antiporter for brain‐specific drug delivery. J Control Release. 2017;254:34‐43. doi:10.1016/j.jconrel.2017.03.034
Cisternino S, Chapy H, André P, Smirnova M, Debray M, Scherrmann JM. Coexistence of passive and proton antiporter‐mediated processes in nicotine transport at the mouse blood‐brain barrier. AAPS J. 2013;15(2):299‐307. doi:10.1208/s12248‐012‐9434‐6
Cong J, Ruan Y, Lyu Q, et al. A proton‐coupled organic cation antiporter is involved in the blood‐brain barrier transport of Aconitum alkaloids. J Ethnopharmacol. 2020;252:112581. doi:10.1016/j.jep.2020.112581
Chapy H, Smirnova M, André P, et al. Carrier‐mediated cocaine transport at the blood‐brain barrier as a putative mechanism in addiction liability. Int J Neuropsychopharmacol. 2014;18(1):pyu001. doi:10.1093/ijnp/pyu001
Kurosawa T, Higuchi K, Okura T, Kobayashi K, Kusuhara H, Deguchi Y. Involvement of proton‐coupled organic cation antiporter in varenicline transport at blood‐brain barrier of rats and in human brain capillary endothelial cells. J Pharm Sci. 2017;106(9):2576‐2582. doi:10.1016/j.xphs.2017.04.032
Fischer W, Neubert RH, Brandsch M. Clonidine accumulation in human neuronal cells. Eur J Pharm Sci. 2007;32(4–5):291‐295. doi:10.1016/j.ejps.2007.08.004
Kitamura A, Higuchi K, Okura T, Deguchi Y. Transport characteristics of tramadol in the blood‐brain barrier. J Pharm Sci. 2014;103(10):3335‐3341. doi:10.1002/jps.24129
Okura T, Hattori A, Takano Y, et al. Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood‐brain barrier transport of oxycodone. Drug Metab Dispos. 2008;36(10):2005‐2013. doi:10.1124/dmd.108.022087
Mizuuchi H, Katsura T, Ashida K, Hashimoto Y, Inui K. Diphenhydramine transport by pH‐dependent tertiary amine transport system in Caco‐2 cells. Am J Physiol Gastrointest Liver Physiol. 2000;278(4):G563‐G569. doi:10.1152/ajpgi.2000.278.4.G563
Kuwayama K, Inoue H, Kanamori T, et al. Uptake of 3,4‐methylenedioxymethamphetamine and its related compounds by a proton‐coupled transport system in Caco‐2 cells. Biochim Biophys Acta. 2008;1778(1):42‐50. doi:10.1016/j.bbamem.2007.08.023
André P, Debray M, Scherrmann JM, Cisternino S. Clonidine transport at the mouse blood‐brain barrier by a new H+ antiporter that interacts with addictive drugs. J Cerebral Blood Flow Metab. 2009;29(7):1293‐1304. doi:10.1038/jcbfm.2009.54
Sachkova A, Doetsch DA, Jensen O, Brockmöller J, Ansari S. How do psychostimulants enter the human brain? Analysis of the role of the proton‐organic cation antiporter. Biochem Pharmacol. 2021;192:114751. doi:10.1016/j.bcp.2021.114751
Redeker KM, Jensen O, Gebauer L, Meyer‐Tönnies MJ, Brockmöller J. Atypical substrates of the organic cation transporter 1. Biomolecules. 2022;12(11):1664. doi:10.3390/biom12111664
Doetsch DA, Ansari S, Jensen O, et al. Substrates of the human brain proton‐organic cation antiporter and comparison with organic cation transporter 1 activities. Int J Mol Sci. 2022;23(15):8430. doi:10.3390/ijms23158430
Kurosawa T, Tega Y, Uchida Y, et al. Proteomics‐based transporter identification by the PICK method: involvement of TM7SF3 and LHFPL6 in proton‐coupled organic cation antiport at the blood‐brain barrier. Pharmaceutics. 2022;14(8):1683. doi:10.3390/pharmaceutics14081683
Kurosawa T, Tega Y, Higuchi K, et al. Expression and functional characterization of drug transporters in brain microvascular endothelial cells derived from human induced pluripotent stem cells. Mol Pharm. 2018;15(12):5546‐5555. doi:10.1021/acs.molpharmaceut.8b00697
Geier EG, Chen EC, Webb A, et al. Profiling solute carrier transporters in the human blood‐brain barrier. Clin Pharmacol Ther. 2013;94(6):636‐639. doi:10.1038/clpt.2013.175
Weksler B, Romero IA, Couraud PO. The hCMEC/D3 cell line as a model of the human blood brain barrier. Fluids Barriers CNS. 2013;10(1):16. doi:10.1186/2045‐8118‐10‐16
Dos Santos Pereira JN, Tadjerpisheh S, Abu Abed M, et al. The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family. AAPS J. 2014;16(6):1247‐1258. doi:10.1208/s12248‐014‐9649‐9
Weksler BB, Subileau EA, Perrière N, et al. Blood‐brain barrier‐specific properties of a human adult brain endothelial cell line. FASEB J. 2005;19(13):1872‐1874. doi:10.1096/fj.04‐3458fje
Redeker KM, Schröder S, Dücker C, Brockmöller J, Gebauer L. Targeted mutagenesis of negatively charged amino acids outlining the substrate translocation path within the human organic cation transporter 3. Biochem Pharmacol. 2024, 223;116188. doi:10.1016/j.bcp.2024.116188
Saadatmand AR, Tadjerpisheh S, Brockmöller J, Tzvetkov MV. The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. Biochem Pharmacol. 2012;83(10):1427‐1434. doi:10.1016/j.bcp.2012.01.032
Gebauer L, Jensen O, Brockmöller J, Dücker C. Substrates and inhibitors of the organic cation transporter 3 and comparison with OCT1 and OCT2. J Med Chem. 2022;65(18):12403‐12416. doi:10.1021/acs.jmedchem.2c01075
Redeker KM, Brockmöller J. Several orphan solute carriers functionally identified as organic cation transporters: substrates specificity compared with known cation transporters. J Biol Chem. 2024;300(9):107629. doi:10.1016/j.jbc.2024.107629
Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150(1):76‐85. doi:10.1016/0003‐2697(85)90442‐7
Tveden‐Nyborg P, Bergmann TK, Jessen N, Simonsen U, Lykkesfeldt J. BCPT 2023 policy for experimental and clinical studies. Basic Clin Pharmacol Toxicol. 2023;133(4):391‐396. doi:10.1111/bcpt.13944
Shimomura K, Okura T, Kato S, et al. Functional expression of a proton‐coupled organic cation (H+/OC) antiporter in human brain capillary endothelial cell line hCMEC/D3, a human blood‐brain barrier model. Fluids Barriers CNS. 2013;10(1):8. doi:10.1186/2045‐8118‐10‐8
Auvity S, Chapy H, Goutal S, et al. Diphenhydramine as a selective probe to study H(+)‐antiporter function at the blood‐brain barrier: application to [(11)C]diphenhydramine positron emission tomography imaging. J Cerebral Blood Flow Metab. 2017;37(6):2185‐2195. doi:10.1177/0271678x16662042
Parvez MM, Sadighi A, Ahn Y, Keller SF, Enoru JO. Uptake transporters at the blood‐brain barrier and their role in brain drug disposition. Pharmaceutics. 2023;15(10). doi:10.3390/pharmaceutics15102473
Sánchez C, Kreilgaard M. R‐citalopram inhibits functional and 5‐HTP‐evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav. 2004;77(2):391‐398. doi:10.1016/j.pbb.2003.12.001
Weber‐Grandke H, Hahn G, Mutschler E, Möhrke W, Langguth P, Spahn‐Langguth H. The pharmacokinetics of tranylcypromine enantiomers in healthy subjects after oral administration of racemic drug and the single enantiomers. Br J Clin Pharmacol. 1993;36(4):363‐365. doi:10.1111/j.1365‐2125.1993.tb00377.x
Petrie B, Mrazova J, Kasprzyk‐Hordern B, Yates K. Multi‐residue analysis of chiral and achiral trace organic contaminants in soil by accelerated solvent extraction and enantioselective liquid chromatography tandem‐mass spectrometry. J Chromatogr A. 2018;1572:62‐71. doi:10.1016/j.chroma.2018.08.034
Tun T, Kang YS. Imperatorin is transported through blood‐brain barrier by carrier‐mediated transporters. Biomolec Ther. 2017;25(4):441‐451. doi:10.4062/biomolther.2017.082
Jakobs W, Ladwig B, Cichon P, Ortel R, Kirch W. Serum levels of articaine 2% and 4% in children. Anesth Prog. 1995;42(3–4):113‐115.
Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1–02):9‐62. doi:10.1055/s‐0043‐116492
Tjandrawinata RR, Setiawati E, Yunaidi DA, Santoso ID, Setiawati A, Susanto LW. Bioequivalence study of two formulations of bisoprolol fumarate film‐coated tablets in healthy subjects. Drug des Devel Ther. 2012;6:311‐316. doi:10.2147/dddt.s36567
Eljebari H, Jebabli N, Salouage I, et al. Population pharmacokinetics of bupivacaine in combined lumbar and sciatic nerve block. Indian J Pharm. 2014;46(2):201‐206. doi:10.4103/0253‐7613.129318
Del Dotto P, Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin Pharmacokinet. 2003;42(7):633‐645. doi:10.2165/00003088‐200342070‐00003
Schran HF, Petryk L, Chang CT, O'Connor R, Gelbert MB. The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single‐component and combination formulations. J Clin Pharmacol. 1996;36(10):911‐922. doi:10.1002/j.1552‐4604.1996.tb04758.x
Scavone JM, Luna BG, Harmatz JS, von Moltke L, Greenblatt DJ. Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. Biopharm Drug Dispos. 1990;11(3):185‐189. doi:10.1002/bdd.2510110302
Malhotra B, Darsey E, Crownover P, Fang J, Glue P. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. Br J Clin Pharmacol. 2011;72(2):226‐234. doi:10.1111/j.1365‐2125.2011.03948.x
Zhou Y, Jiang J, Hu P, Wang H. A high‐performance liquid chromatography‐tandem mass spectrometry method coupled with protein precipitation for determination of granisetron in human plasma and its application to a comparative pharmacokinetic study. Biomed Chromatogr: BMC. 2014;28(12):1597‐1600. doi:10.1002/bmc.3233
Domino EF. Taming the ketamine tiger. 1965. Anesthesiology. 2010;113(3):678‐684. doi:10.1097/ALN.0b013e3181ed09a2
Follath F, Ganzinger U, Schuetz E. Reliability of antiarrhythmic drug plasma concentration monitoring. Clin Pharmacokinet. 1983;8(1):63‐82. doi:10.2165/00003088‐198308010‐00004
Scarparo HC, Maia RN, Filho ED, et al. Plasma mepivacaine concentrations in patients undergoing third molar surgery. Aust Dent J. 2016;61(4):446‐454. doi:10.1111/adj.12410
Kirchheiner J, Heesch C, Bauer S, et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2004;76(4):302‐312. doi:10.1016/j.clpt.2004.07.002
Hunt TL, Gallagher SC, Cullen MT Jr, Shah AK. Evaluation of safety and pharmacokinetics of consecutive multiple‐day dosing of palonosetron in healthy subjects. J Clin Pharmacol. 2005;45(5):589‐596. doi:10.1177/0091270005275061
Cho SH, Lee HW, Im HT, Park WS, Baek M, Lee KT. Quantification of propiverine by liquid chromatography/electrospray tandem mass spectrometry: application to a bioequivalence study of two formulations in healthy subjects. J Pharm Biomed Anal. 2005;39(3–4):670‐676. doi:10.1016/j.jpba.2005.03.038
Tompson DJ, Vearer D. Steady‐state pharmacokinetic properties of a 24‐hour prolonged‐release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease. Clin Ther. 2007;29(12):2654‐2666. doi:10.1016/j.clinthera.2007.12.010
Gromov K, Grassin‐Delyle S, Foss NB, et al. Population pharmacokinetics of ropivacaine used for local infiltration anaesthesia during primary total unilateral and simultaneous bilateral knee arthroplasty. Br J Anaesth. 2021;126(4):872‐880. doi:10.1016/j.bja.2020.11.038
Renner UD, Oertel R, Kirch W. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. Ther Drug Monit. 2005;27(5):655‐665. doi:10.1097/01.ftd.0000168293.48226.57
Doroshyenko O, Fuhr U. Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281‐302. doi:10.2165/00003088‐200948050‐00001
Franco‐Salinas G, de la Rosette JJ, Michel MC. Pharmacokinetics and pharmacodynamics of tamsulosin in its modified‐release and oral controlled absorption system formulations. Clin Pharmacokinet. 2010;49(3):177‐188. doi:10.2165/11317580‐000000000‐00000
Liu M, Zhang D, Yang M, et al. Pharmacokinetics of terazosin enantiomers in healthy Chinese male subjects. Chirality. 2012;24(12):1047‐1050. doi:10.1002/chir.22095
Cacek AT, Gobburu JV, Gopalakrishnan M. Population pharmacokinetics of an intranasally administered combination of oxymetazoline and tetracaine in healthy volunteers. J Clin Pharmacol. 2017;57(2):247‐254. doi:10.1002/jcph.799
Kirchheiner J, Müller G, Meineke I, Wernecke KD, Roots I, Brockmöller J. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol. 2003;23(5):459‐466. doi:10.1097/01.jcp.0000088909.24613.92
Matthaei J, Kuron D, Faltraco F, et al. OCT1 mediates hepatic uptake of sumatriptan and loss‐of‐function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin Pharmacol Ther. 2016;99(6):633‐641. doi:10.1002/cpt.317
Tzvetkov MV, Matthaei J, Pojar S, et al. Increased systemic exposure and stronger cardiovascular and metabolic adverse reactions to fenoterol in individuals with heritable OCT1 deficiency. Clin Pharmacol Ther. 2018;103(5):868‐878. doi:10.1002/cpt.812
Gottesman MM, Ambudkar SV, Xia D. Structure of a multidrug transporter. Nat Biotechnol. 2009;27(6):546‐547. doi:10.1038/nbt0609‐546
Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM. Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997;51(6):913‐921. doi:10.1124/mol.51.6.913
Gründemann D, Harlfinger S, Golz S, et al. Discovery of the ergothioneine transporter. Proc Natl Acad Sci U S A. 2005;102(14):5256‐5261. doi:10.1073/pnas.0408624102
Tang NL, Ganapathy V, Wu X, et al. Mutations of OCTN2, an organic cation/carnitine transporter, lead to deficient cellular carnitine uptake in primary carnitine deficiency. Hum Mol Genet. 1999;8(4):655‐660. doi:10.1093/hmg/8.4.655
Gorboulev V, Ulzheimer JC, Akhoundova A, et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997;16(7):871‐881. doi:10.1089/dna.1997.16.871
Higuchi K, Kitamura A, Okura T, Deguchi Y. Memantine transport by a proton‐coupled organic cation antiporter in hCMEC/D3 cells, an in vitro human blood‐brain barrier model. Drug Metab Pharmacokinet. 2015;30(2):182‐187. doi:10.1016/j.dmpk.2014.12.006
Chapy H, Goracci L, Vayer P, et al. Pharmacophore‐based discovery of inhibitors of a novel drug/proton antiporter in human brain endothelial hCMEC/D3 cell line. Br J Pharmacol. 2015;172(20):4888‐4904. doi:10.1111/bph.13258